Notice: This company has been marked as potentially delisted and may not be actively trading. Reneo Pharmaceuticals (RPHM) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get the Latest News and Ratings for RPHM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Reneo Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up RPHM Analyst Ratings Over TimeTypeCurrent Forecast12/23/23 to 12/22/241 Month Ago11/23/23 to 11/22/243 Months Ago9/24/23 to 9/23/241 Year Ago12/23/22 to 12/23/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)Hold1 Hold rating(s)7 Hold rating(s)7 Hold rating(s)7 Hold rating(s)Sell0 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$1.50$2.83$11.01$18.14Forecasted Upside-17.58% Downside55.68% Upside698.01% Upside1,233.64% UpsideConsensus RatingHoldReduceReduceReduce Your chance to get on the next “60-Second Trade” (Ad)Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! RPHM Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History RPHM Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Reneo Pharmaceuticals Stock vs. The CompetitionTypeReneo PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.00 2.81 2.51Consensus RatingHoldModerate BuyModerate BuyPredicted Upside-17.58% Downside25,827.32% Upside14.53% UpsideNews Sentiment RatingNeutral NewsSee Recent RPHM NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/14/2024HC Wainwright2 of 5 starsM. KapoorSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.50-5.66%12/15/2023Leerink Partners1 of 5 stars Reiterated RatingOutperform ➝ Market Perform12/15/2023Jefferies Financial Group2 of 5 stars Reiterated RatingBuy ➝ Hold12/14/2023LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Neutral12/14/2023Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Underperform12/14/2023William BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingM. MinterSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform12/14/2023Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOverweight ➝ Neutral$25.00 ➝ $4.00+247.82%12/14/2023Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOutperform ➝ Neutral$28.00 ➝ $3.00+160.87%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:17 AM ET. RPHM Forecast - Frequently Asked Questions What is Reneo Pharmaceuticals' forecast for 2025? According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Reneo Pharmaceuticals is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. Should I buy or sell Reneo Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There is currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RPHM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RPHM, but not buy additional shares or sell existing shares. Does Reneo Pharmaceuticals's stock price have much downside? According to analysts, Reneo Pharmaceuticals's stock has a predicted downside of -17.58% based on their 12-month stock forecasts. Do Wall Street analysts like Reneo Pharmaceuticals more than its competitors? Analysts like Reneo Pharmaceuticals less than other "medical" companies. The consensus rating for Reneo Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RPHM compares to other companies. Stock Forecasts and Research Tools Related Companies Fulcrum Therapeutics Stock Forecast Aurora Cannabis Stock Forecast Lexeo Therapeutics Stock Forecast Tenaya Therapeutics Stock Forecast Fate Therapeutics Stock Forecast DiaMedica Therapeutics Stock Forecast Atai Life Sciences Stock Forecast Zentalis Pharmaceuticals Stock Forecast Acrivon Therapeutics Stock Forecast Molecular Partners Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Your chance to get on the next “60-Second Trade” (Ad)Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! This page (NASDAQ:RPHM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reneo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
